Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ABUS Arbutus Biopharma Corp
- Stocks
- Healthcare
- NASDAQ: ABUS
Price (delayed)
$3.09
Market cap
$591.82M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.41
Enterprise value
$560.34M
Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple
Highlights
The debt has declined by 31% year-on-year and by 8% since the previous quarter
Arbutus Biopharma's gross profit has shrunk by 51% YoY but it has increased by 3.8% QoQ
Arbutus Biopharma's revenue has shrunk by 51% YoY but it has increased by 3.8% QoQ
Arbutus Biopharma's equity has decreased by 31% YoY and by 19% QoQ
ABUS's quick ratio is down by 27% QoQ and by 9% YoY
Key stats
What are the main financial stats of ABUS
Market
Valuations
Earnings
Shares outstanding
191.53M
Market cap
$591.82M
Enterprise value
$560.34M
Price to earnings (P/E)
N/A
Price to book (P/B)
7.47
Price to sales (P/S)
92.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
87.51
Revenue
$6.4M
Gross profit
$6.4M
Operating income
-$79.91M
Net income
-$76.57M
EBIT
-$76.45M
EBITDA
-$75.1M
Free cash flow
-$59.03M
Per share
Balance sheet
Liquidity
EPS
-$0.41
EPS diluted
-$0.41
Free cash flow per share
-$0.31
Book value per share
$0.41
Revenue per share
$0.03
TBVPS
$0.61
Total assets
$117.01M
Total liabilities
$37.85M
Debt
$5.6M
Equity
$79.16M
Working capital
$97.38M
Debt to equity
0.07
Current ratio
6.01
Quick ratio
5.86
Net debt/EBITDA
0.42
Margins
Efficiency
Dividend
EBITDA margin
-1,172.8%
Gross margin
100%
Net margin
-1,195.9%
Operating margin
-1,248%
Return on assets
-55.8%
Return on equity
-75.5%
Return on invested capital
-92.5%
Return on capital employed
-78.3%
Return on sales
-1,194%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ABUS stock price
How has the Arbutus Biopharma stock price performed over time
Intraday
-1.28%
1 week
-9.38%
1 month
-8.04%
1 year
0%
YTD
-5.5%
QTD
-11.46%
Financial performance
How have Arbutus Biopharma's revenue and profit performed over time
Revenue
$6.4M
Gross profit
$6.4M
Operating income
-$79.91M
Net income
-$76.57M
Gross margin
100%
Net margin
-1,195.9%
The net margin has dropped by 109% year-on-year and by 6% since the previous quarter
ABUS's operating margin has dropped by 102% year-on-year and by 4.5% since the previous quarter
Arbutus Biopharma's gross profit has shrunk by 51% YoY but it has increased by 3.8% QoQ
Arbutus Biopharma's revenue has shrunk by 51% YoY but it has increased by 3.8% QoQ
Price vs fundamentals
How does ABUS's price correlate with its fundamentals
Growth
What is Arbutus Biopharma's growth rate over time
Valuation
What is Arbutus Biopharma stock price valuation
P/E
N/A
P/B
7.47
P/S
92.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
87.51
The company's EPS fell by 8% QoQ but it rose by 7% YoY
ABUS's price to book (P/B) is 110% higher than its 5-year quarterly average of 3.6 and 15% higher than its last 4 quarters average of 6.6
Arbutus Biopharma's equity has decreased by 31% YoY and by 19% QoQ
The price to sales (P/S) is 141% higher than the 5-year quarterly average of 38.7
Arbutus Biopharma's revenue has shrunk by 51% YoY but it has increased by 3.8% QoQ
Efficiency
How efficient is Arbutus Biopharma business performance
The company's return on sales has shrunk by 109% YoY and by 6% QoQ
The ROIC has declined by 45% year-on-year and by 19% since the previous quarter
The ROE is down by 20% year-on-year and by 19% since the previous quarter
Arbutus Biopharma's return on assets has decreased by 18% YoY and by 16% QoQ
Dividends
What is ABUS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ABUS.
Financial health
How did Arbutus Biopharma financials performed over time
ABUS's quick ratio is down by 27% QoQ and by 9% YoY
The company's current ratio fell by 26% QoQ and by 10% YoY
The debt is 93% smaller than the equity
Arbutus Biopharma's equity has decreased by 31% YoY and by 19% QoQ
The debt has declined by 31% year-on-year and by 8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.